HELSE STAVANGER HF

Their core work

Stavanger University Hospital is a major Norwegian hospital trust that contributes clinical expertise and patient data to European health research consortia. Their work spans chronic disease management, digital health monitoring, and AI-driven pathology — always from the clinical end, bringing real-world patient populations and hospital infrastructure to multi-site trials. They are a clinical partner that grounds research in actual care delivery, particularly in autoimmune diseases, neurodegenerative conditions, and cancer survivorship.

What they specialise in

How they've shifted over time

Their early H2020 involvement (2016–2017) was diverse, including disaster response (ANYWHERE) and clinical communication training (TALK) — suggesting an institution exploring where its strengths fit in EU research. From 2019 onward, the focus sharpened decisively toward chronic disease, digital health, and data-driven clinical research, with four projects launched in 2019 alone covering autoimmune disease, Parkinson's, digital endpoints, and AI pathology. The most recent project (REBECCA, 2021) confirms a clear trajectory toward using digital tools and real-world data to improve long-term patient outcomes.

Moving firmly toward digital endpoints, wearable monitoring, and real-world evidence for chronic disease management — expect future involvement in decentralized clinical trials and AI-assisted patient monitoring.

How they like to work

Stavanger University Hospital operates exclusively as a participant, never coordinating — a pattern consistent with a clinical site contributing patients, data, and medical expertise to researcher-led consortia. With 140 unique partners across 22 countries, they are well-networked and comfortable in large multi-site projects. Their value proposition is clear: they bring a real hospital environment with real patients to validate what others develop.

Broad European network spanning 140 partners across 22 countries, reflecting their role as a sought-after clinical site in large multi-national health consortia. No strong geographic clustering — they work across the continent wherever the research question demands a Nordic clinical partner.

What sets them apart

As one of Norway's largest hospital trusts, Stavanger brings something many research institutions cannot: direct access to patient populations, clinical workflows, and hospital infrastructure within a well-organized Nordic healthcare system. Their combination of clinical trial capability with growing digital health and AI expertise makes them particularly valuable for projects that need to bridge the gap between technology development and clinical validation. For consortium builders, they offer a credible, experienced clinical endpoint in a country known for high-quality patient registries and health data infrastructure.

Highlights from their portfolio

• REBECCA
  Largest funding share (EUR 755K) and most recent project, combining wearables, causal modelling, and real-world data to address breast cancer survivorship — signals their strategic direction.
• IDEA-FAST
  Major IMI-style project developing digital endpoints for fatigue and sleep across multiple chronic diseases, positioning Stavanger at the intersection of clinical medicine and digital health.
• CLARIFY
  Their entry into AI-powered pathology using cloud computing and machine learning, representing a capability expansion beyond traditional clinical trial participation.